Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Uliledlimab/Toripalimab Combo Demonstrates Efficacy and Safety in Advanced NSCLC

May 27th 2022, 7:00pm

ASCO Annual Meeting

Uliledlimab in combination with toripalimab generated notable response rates in patients with advanced non–small cell lung cancer who were previously ineligible to receive standard-of-care treatment.

Black Patients Less Likely to Trust Clinical Trials in Breast Cancer

May 26th 2022, 9:00pm

ASCO Annual Meeting

Black patients were less likely to be included in clinical trials that investigate newer treatments for metastatic breast cancer, despite having the highest death rate and shortest survival outcomes when compared with other racial and ethnic groups in the United States.

Disparities Remain Regarding Access to Telehealth

May 26th 2022, 9:00pm

Disparities in access to telehealth for cancer care were seen across more than 20 tumor types, according to study findings that were presented during a press briefing ahead of the 2022 ASCO Annual Meeting.

Hispanic Ethnicity Associated With Poorer OS in Pediatric Neuroblastoma

May 26th 2022, 9:00pm

ASCO Annual Meeting

Non-White Hispanic children and those with public insurance care in a clinical trial for high-risk neuroblastoma had inferior overall survival rates compared with other children.

Frontline Datopotamab Deruxtecan/Durvalumab Combo Elicits Encouraging Responses in TNBC

May 19th 2022, 3:00pm

The combination of the TROP2-directed antibody-drug conjugate datopotamab deruxtecan and durvalumab showcased early activity with acceptable safety when used as first-line treatment in patients with locally advanced or metastatic triple-negative breast cancer, according to data from the phase 1b/2 BEGONIA trial.

Tislelizumab Plus Nab-Paclitaxel Yields Preliminary Efficacy in NMBIC

May 18th 2022, 1:00pm

The combination of tislelizumab plus nab-paclitaxel demonstrated benefit and a tolerable safety profile in patients with high-risk non–muscle invasive bladder cancer.

Sabizabulin Yields Encouraging rPFS, Tolerable Toxicity Profile in Previously Treated mCRPC

May 17th 2022, 5:00pm

The utilization of sabizabulin in patients with metastatic castration-resistant prostate cancer who progressed on androgen receptor-targeting therapy yielded significant and durable objective tumor responses, according to results of a phase 1b/2 trial (NCT03752099).

Immunotherapy Plus Nadofaragene Firadenovec Could Display Synergistic Activity in NMIBC

May 17th 2022, 4:00pm

Nadofaragene firadenovec combined with immune checkpoint inhibitors such as pembrolizumab may play a synergistic role in the treatment of patients with Bacillus Calmette–Guérin-unresponsive non–muscle invasive bladder cancer.

Antegrade Administration of Mitomycin Gel Provides Safe, Effective Approach in Upper Tract Urothelial Carcinoma

May 16th 2022, 11:13pm

American Urological Association Annual Meeting

Data from a retrospective analysis demonstrated that mitomycin gel was safe and effective when administered using an antegrade approach in real-world populations of patients with low-grade upper tract urothelial cancer.

Neoadjuvant Tislelizumab/Nab-Paclitaxel Combo Produces Early Activity in MIBC

May 16th 2022, 10:43pm

American Urological Association Annual Meeting

The combination of neoadjuvant tislelizumab and nab-paclitaxel elicited a high rate of pathologic complete response in patients with muscle-invasive bladder cancer, according to preliminary findings from the phase 2 TRUCE-01 trial.

Dr. Ghali on Nectin-4 and TROP-2 Expression in Urothelial, Variant Histology Bladder Cancer

May 16th 2022, 8:27pm

American Urological Association Annual Meeting

Fady Ghali, MD, discusses the expression of Nectin-4 and TROP-2 in variant histology bladder cancer and urothelial cancer.

Dr. Nguyen on the Efficacy of IS-002 for Robotic Prostatectomy in Prostate Cancer

May 16th 2022, 7:27pm

American Urological Association Annual Meeting

Hao G. Nguyen MD, PhD, discusses the efficacy and safety of IS-002, a prostate-specific membrane antigen–targeting fluorophore, for image-guided surgery in patients with prostate cancer undergoing robotic prostatectomy.

TROP-2, Nectin-4 Are Highly Expressed in Urothelial, Variant Histology Bladder Cancer

May 16th 2022, 5:41pm

American Urological Association Annual Meeting

TROP-2 and Nectin-4, surface cell targets of sacituzumab govitecan and enfortumab vedotin, respectively, are highly expressed in urothelial cancer and variant histology bladder cancer.

Infigratinib Generates Activity in FGFR-Mutated Urothelial Carcinoma

May 16th 2022, 5:29pm

American Urological Association Annual Meeting

Infigratinib yielded notable activity and tolerability in patients with localized upper tract urothelial carcinoma harboring FGFR1/2/3 mutations.

IS-002 Improves Prostate Cancer Visualization Prior to Robotic Prostatectomy

May 16th 2022, 5:11pm

American Urological Association Annual Meeting

The novel, near-infrared, prostate-specific membrane antigen-targeted fluorophore IS-002 was safe, well-tolerated, and allowed for enhanced intraoperative tumor detection in patients undergoing robotic prostatectomy.

Quality of Life Is Maintained With Mitomycin Gel in Low-Grade Non–Muscle Invasive Bladder Cancer

May 16th 2022, 5:00pm

American Urological Association Annual Meeting

Patients with low-grade non-muscle invasive bladder cancer who received the chemoablative reverse thermal gel UGN-102 were found to have maintained health-related quality-of-life outcomes.

Dr. Mitra on Nadofaragene Firadenovec Plus Anti–PD-1 Therapy in BCG-Unresponsive NMIBC

May 16th 2022, 3:00pm

American Urological Association Annual Meeting

Anirban P. Mitra, MD, PhD, discusses data from an assessment of PD-1 and PD-L1 status on transurethral resection specimens collected from patients with non–muscle-invasive bladder cancer who received nadofaragene firadenovec as part of a phase 3 trial.

Neoadjuvant Axitinib Effective in Subgroup of Patients with Renal Cell Carcinoma

May 16th 2022, 1:59pm

American Urological Association Annual Meeting

Neoadjuvant axitinib facilitated partial nephrectomy in patients with clear cell renal cell carcinoma and complex masses with an imperative indication for nephron-sparing surgery but no viable pathway to receive the procedure.

Darolutamide Added to ADT/Docetaxel Shows No Increased Toxicity in mHSPC

May 16th 2022, 1:45pm

American Urological Association Annual Meeting

The combination of darolutamide plus androgen deprivation therapy and docetaxel presents adverse effects that are similar to those experienced with ADT plus docetaxel alone in patients with metastatic hormone-sensitive prostate cancer.

Positive Harm-Benefit Data Found in PSA Screening for Black Patients With Prostate Cancer

May 15th 2022, 11:29pm

American Urological Association Annual Meeting

Complementary approaches to quantifying overdiagnosis generated a more beneficial harm-benefit tradeoff of prostate-specific antigen screening, compared with previous estimates that used shorter follow-up from the introduction of screening.